In-Series Versus In-Parallel Mechanical Circulatory Support for the Right Heart: A Simulation Study.

Right heart failure (RHF) is a serious health issue with increasing incidence and high mortality. Right ventricular assist devices (RVADs) have been used to support the end-stage failing right ventricle (RV). Current RVADs operate in parallel with native RV, which alter blood flow pattern and increase RV afterload, associated with high tension in cardiac muscles and long-term valve complications. We are developing an in-series RVAD for better RV unloading. This article presents a mathematical model to compare the effects of RV unloading and hemodynamic restoration on an overloaded or failing RV. The model was used to simulate both in-series (sRVAD) and in-parallel (pRVAD) (right atrium-pulmonary artery cannulation) support for severe RHF. The results demonstrated that sRVAD more effectively unloads the RV and restores the balance between RV oxygen supply and demand in RHF patients. In comparison to simulated pRVAD and published clinical and in silico studies, the sRVAD was able to provide comparable restoration of key hemodynamic parameters and demonstrated superior afterload and volume reduction. This study concluded that in-series support was able to produce effective afterload reduction and preserve the valve functionality and native blood flow pattern, eliminating complications associated with in-parallel support.

Selective reduction of afterload in right heart assist therapy: a mock loop study†.

OBJECTIVES: The treatment of right ventricular failure is closely linked to effects on pulmonary vascular resistance and thus the right ventricular (RV) afterload. Medical therapy includes afterload-decreasing drugs such as nitric oxide and prostacycline. However, current devices for mechanical unloading of the right ventricle aim at a decrease in preload increasing the pulmonary volume loading. In our concept study, we tested a minimally invasive right ventricular assist device (MIRVAD) that specifically reduces the afterload. METHODS: The MIRVAD is supposed to be a foldable device for temporary transvascular placement in the pulmonary artery. We incorporated a MIRVAD prototype into a mock circulatory loop that can reproduce haemodynamic interaction between the pump and the physiological system. Pulmonary hypertension (PH), right heart failure (RHF) and MIRVAD-assisted cases were simulated. The key haemodynamic parameters for RV unloading were recorded. RESULTS: Mock loop simulation attested to a sufficient right ventricular unloading by serial application of a miniaturized impeller pump in the pulmonary artery. The afterload, represented by the pulmonary arterial root pressure, was recovered to the healthy range (32.62-10.93 mmHg) for the simulated PH case. In the simulated RHF case, the impaired pulmonary perfusion increased from 43.4 to 88.8% of the healthy level and the total ventricular work reduced from 0.381 to 0.197 J at a pump speed of 3500 rpm. At pump speeds higher than 3500 rpm, the pulmonary valve remains constantly open and the right ventricular configuration changes into a simple perfused hollow body. CONCLUSIONS: The feasibility of RV unloading by a selective decrease in RV afterload was proved in principle. By alternation of the pump speed, gradual reloading in sense of a myocardial training may be achieved. The results will be validated by future animal trials where the relationship between the level of support and pulmonary vascular pressure can be investigated in vivo. Further device design concerning foldable impeller leaflets will be carried out. At a final stage, the crimped version is supposed to reach a size below 1 cm to facilitate minimally invasive insertion.